



FOR IMMEDIATE RELEASE

**Molecular Targeting Technologies, Inc. Wins Award from
“RESI Boston 2017” Innovation Challenge**

**Early-stage investors applaud MTTI’s TDURA as a potentially
transformational platform for precision medicine**



Greg Mannix, VP International Business Development, Life Science Nation; Chris Pak, President & CEO, MTTI; Michael Silvon, SVP Business Development, MTTI

West Chester, Pa, September 28, 2017---Molecular Targeting Technologies, Inc. (MTTI) announces today that it has been awarded the Second Prize in the Life Science Nation “RESI (Redefining Early Stage Investment) Boston 2017” investment competition for early-stage life science companies. MTTI was nominated and sponsored by NHLBI (National Heart Lung & Blood Institute) of National Institutes of Health (NIH) for this event. MTTI presented its novel TDURA platform technology at this conference.

TDURA is an imaging agent with a unique mechanism to "see" cell death. It is fast, sensitive and enables early, actionable tracking of cell damage, reducing toxicity, improving outcomes and cutting healthcare costs. TDURA detected chemotherapy related cardiac dysfunction much earlier than existing technologies and detected tumor response and distinguished responders from non-responders as early as 1-day post-chemotherapy. MTTI is seeking funding for clinical development.

“I enjoyed getting to know the MTTI team and their project. They competed very well with over 150 companies to get a chance to present at the RESI conference in Boston. I was very impressed with their technology, so I wasn’t surprised they scored so well in the competition. Congratulations to Chris Pak and his team!”
Greg Mannix, Vice President of International Business Development at Life Science Nations (LSN), organizers of the RESI conference series.

“We are honored to receive this prestigious award from LSN. We are grateful to NHLBI for funding the TDURA project and nominating us for this Innovation Challenge. TDURA represents a potentially transformational platform for precision medicine,” said Chris Pak, President & CEO of MTTI.

Molecular Targeting Technologies, Inc. (MTTI) is a privately held biotechnology company primarily focused on the acquisition and development of novel technologies for treatment and diagnosis of diseases. More information: www.mtarget.com.

Contact: Chris Pak, Email: cpak@mtarget.com; Tel: (610) 738-7938.